Medications Linked to Carpal Tunnel Syndrome in Major Pharmacovigilance Study
Background
Carpal Tunnel Syndrome (CTS) is a common condition causing pain, numbness, and tingling in the hand and arm, often due to compression of the median nerve. While typically associated with repetitive strain or anatomical factors, an increasing body of evidence suggests certain medications might contribute to its development. This study aimed to systematically identify specific drug classes and individual medications associated with an increased risk of CTS using real-world pharmacovigilance data.
Results
The analysis identified several drug classes with a significant association with CTS. Notably, aromatase inhibitors (used in breast cancer treatment) showed a 3.2-fold increased ROR (p<0.001), with anastrozole specifically linked to 4,500 reports of CTS. Fluoroquinolone antibiotics also demonstrated a 1.8-fold increased ROR (p<0.01), with levofloxacin being the most frequently reported. The study found that oral contraceptives containing ethinyl estradiol and levonorgestrel were associated with a 2.5-fold higher reporting odds of CTS (p<0.001), accounting for over 7,000 cases in the database. Additionally, thiazolidinediones (diabetes medications) like pioglitazone showed a 1.5-fold increase (p<0.05), and statins had a modest but significant 1.2-fold increase (p<0.05). Overall, over 25,000 reports of CTS were potentially linked to medication use.
Why It Matters
This study provides critical evidence linking specific medications to Carpal Tunnel Syndrome, highlighting a previously underrecognized risk. The findings could lead to updated prescribing guidelines and enhanced patient monitoring, particularly for individuals at higher risk of CTS who are prescribed these drugs. Future research should focus on mechanistic studies to understand how these medications induce CTS and consider prospective clinical trials to confirm these associations.